Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.36
MDT's Cash-to-Debt is ranked lower than
81% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. MDT: 0.36 )
Ranked among companies with meaningful Cash-to-Debt only.
MDT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.02 Max: No Debt
Current: 0.36
Equity-to-Asset 0.51
MDT's Equity-to-Asset is ranked lower than
66% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDT: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
MDT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.64 Max: 0.82
Current: 0.51
0.37
0.82
Interest Coverage 4.05
MDT's Interest Coverage is ranked lower than
88% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. MDT: 4.05 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s Interest Coverage Range Over the Past 10 Years
Min: 3.82  Med: 10.69 Max: 16.28
Current: 4.05
3.82
16.28
Piotroski F-Score: 6
Altman Z-Score: 2.80
Beneish M-Score: -2.48
WACC vs ROIC
6.52%
6.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.72
MDT's Operating Margin % is ranked higher than
86% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. MDT: 17.72 )
Ranked among companies with meaningful Operating Margin % only.
MDT' s Operating Margin % Range Over the Past 10 Years
Min: 16.71  Med: 23.03 Max: 30.17
Current: 17.72
16.71
30.17
Net Margin % 13.51
MDT's Net Margin % is ranked higher than
83% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. MDT: 13.51 )
Ranked among companies with meaningful Net Margin % only.
MDT' s Net Margin % Range Over the Past 10 Years
Min: 12.27  Med: 18.81 Max: 22.78
Current: 13.51
12.27
22.78
ROE % 7.83
MDT's ROE % is ranked higher than
64% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. MDT: 7.83 )
Ranked among companies with meaningful ROE % only.
MDT' s ROE % Range Over the Past 10 Years
Min: 6.72  Med: 19.6 Max: 27.52
Current: 7.83
6.72
27.52
ROA % 3.99
MDT's ROA % is ranked higher than
65% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. MDT: 3.99 )
Ranked among companies with meaningful ROA % only.
MDT' s ROA % Range Over the Past 10 Years
Min: 3.43  Med: 10.42 Max: 14.3
Current: 3.99
3.43
14.3
ROC (Joel Greenblatt) % 58.79
MDT's ROC (Joel Greenblatt) % is ranked higher than
90% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. MDT: 58.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.21  Med: 66.98 Max: 82.85
Current: 58.79
51.21
82.85
3-Year Revenue Growth Rate 7.80
MDT's 3-Year Revenue Growth Rate is ranked higher than
63% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. MDT: 7.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.2  Med: 14.1 Max: 18.6
Current: 7.8
4.2
18.6
3-Year EBITDA Growth Rate 4.10
MDT's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. MDT: 4.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MDT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -15.5  Med: 13.2 Max: 45.5
Current: 4.1
-15.5
45.5
3-Year EPS without NRI Growth Rate -9.70
MDT's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. MDT: -9.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MDT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 15.6 Max: 27.1
Current: -9.7
-9.7
27.1
» MDT's 30-Y Financials

Financials (Next Earnings Date: 2017-05-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MDT Guru Trades in Q2 2016

T Rowe Price Equity Income Fund 750,000 sh (New)
Jim Simons 573,141 sh (New)
Joel Greenblatt 167,825 sh (New)
Paul Tudor Jones 4,000 sh (New)
Steven Cohen 125,000 sh (New)
Jeremy Grantham 4,444,824 sh (+19.91%)
Pioneer Investments 4,975,460 sh (+7.69%)
Vanguard Health Care Fund 19,159,633 sh (+4.51%)
David Carlson 930,000 sh (unchged)
Bill Nygren 2,490,000 sh (unchged)
George Soros Sold Out
Jeff Auxier 139,173 sh (-0.43%)
Mairs and Power 2,994,818 sh (-0.76%)
PRIMECAP Management 14,981,004 sh (-1.42%)
Diamond Hill Capital 2,470,305 sh (-1.79%)
Dodge & Cox 6,452,264 sh (-5.64%)
Ken Fisher 4,716 sh (-6.02%)
John Buckingham 21,869 sh (-6.23%)
Keeley Asset Management Corp 11,133 sh (-8.54%)
Manning & Napier Advisors, Inc 7,062,815 sh (-9.40%)
Mario Gabelli 34,285 sh (-9.48%)
Ruane Cunniff 3,395 sh (-12.84%)
Barrow, Hanley, Mewhinney & Strauss 21,090,262 sh (-23.29%)
John Hussman 125,000 sh (-28.57%)
HOTCHKIS & WILEY 1,653,662 sh (-30.34%)
Robert Olstein 66,000 sh (-31.25%)
First Eagle Investment 1,106,014 sh (-39.69%)
» More
Q3 2016

MDT Guru Trades in Q3 2016

Ray Dalio 31,000 sh (New)
Eaton Vance Worldwide Health Sciences Fund 665,629 sh (New)
Ken Fisher 4,949 sh (+4.94%)
Jeremy Grantham 4,593,000 sh (+3.33%)
Paul Tudor Jones 4,100 sh (+2.50%)
T Rowe Price Equity Income Fund 750,000 sh (unchged)
John Hussman 125,000 sh (unchged)
David Carlson 930,000 sh (unchged)
Keeley Asset Management Corp 11,133 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Jeff Auxier 139,123 sh (-0.04%)
Mairs and Power 2,960,586 sh (-1.14%)
Vanguard Health Care Fund 18,747,933 sh (-2.15%)
PRIMECAP Management 14,482,669 sh (-3.33%)
Diamond Hill Capital 2,385,913 sh (-3.42%)
Pioneer Investments 4,769,969 sh (-4.13%)
Manning & Napier Advisors, Inc 6,658,775 sh (-5.72%)
Barrow, Hanley, Mewhinney & Strauss 19,033,448 sh (-9.75%)
Ruane Cunniff 3,000 sh (-11.63%)
Dodge & Cox 5,584,858 sh (-13.44%)
Mario Gabelli 26,273 sh (-23.37%)
Robert Olstein 48,432 sh (-26.62%)
John Buckingham 16,032 sh (-26.69%)
Signature Select Canadian Fund 78,800 sh (-37.90%)
HOTCHKIS & WILEY 1,012,932 sh (-38.75%)
Bill Nygren 1,140,000 sh (-54.22%)
First Eagle Investment 397,038 sh (-64.10%)
Jim Simons 191,241 sh (-66.63%)
» More
Q4 2016

MDT Guru Trades in Q4 2016

Richard Pzena 4,287 sh (New)
Paul Tudor Jones 42,798 sh (+943.85%)
Jim Simons 878,141 sh (+359.18%)
T Rowe Price Equity Income Fund 1,810,000 sh (+141.33%)
Robert Olstein 110,000 sh (+127.12%)
Ray Dalio 62,300 sh (+100.97%)
Dodge & Cox 10,688,625 sh (+91.39%)
Bill Nygren 1,640,000 sh (+43.86%)
HOTCHKIS & WILEY 1,251,351 sh (+23.54%)
Ken Fisher 6,096 sh (+23.18%)
John Buckingham 18,321 sh (+14.28%)
Pioneer Investments 5,253,307 sh (+10.13%)
Diamond Hill Capital 2,615,402 sh (+9.62%)
Barrow, Hanley, Mewhinney & Strauss 20,528,595 sh (+7.86%)
Mairs and Power 3,142,079 sh (+6.13%)
Jeff Auxier 146,923 sh (+5.61%)
David Carlson 970,000 sh (+4.30%)
Vanguard Health Care Fund 19,256,523 sh (+2.71%)
Mario Gabelli 26,774 sh (+1.91%)
Manning & Napier Advisors, Inc 6,772,888 sh (+1.71%)
John Hussman 125,000 sh (unchged)
Ruane Cunniff 3,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 665,629 sh (unchged)
Keeley Asset Management Corp Sold Out
Jeremy Grantham 4,309,570 sh (-6.17%)
PRIMECAP Management 12,767,922 sh (-11.84%)
First Eagle Investment 1,434 sh (-99.64%)
» More
Q1 2017

MDT Guru Trades in Q1 2017

NWQ Managers 3,432 sh (New)
Louis Moore Bacon 25,000 sh (New)
Steven Cohen 186,100 sh (New)
Joel Greenblatt 224,898 sh (New)
Caxton Associates 6,900 sh (New)
T Rowe Price Equity Income Fund 2,750,000 sh (+51.93%)
Ken Fisher 7,109 sh (+16.62%)
Dodge & Cox 12,212,276 sh (+14.25%)
Mairs and Power 3,473,906 sh (+10.56%)
Robert Olstein 121,000 sh (+10.00%)
Richard Pzena 4,560 sh (+6.37%)
Jeff Auxier 147,023 sh (+0.07%)
First Eagle Investment 1,434 sh (unchged)
Ruane Cunniff 3,000 sh (unchged)
David Carlson 970,000 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Jim Simons Sold Out
Diamond Hill Capital 2,597,862 sh (-0.67%)
John Buckingham 18,175 sh (-0.80%)
HOTCHKIS & WILEY 1,235,797 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 20,205,859 sh (-1.57%)
Pioneer Investments 5,132,545 sh (-2.30%)
Jeremy Grantham 4,205,711 sh (-2.41%)
Vanguard Health Care Fund 18,760,219 sh (-2.58%)
Mario Gabelli 25,861 sh (-3.41%)
PRIMECAP Management 11,093,565 sh (-13.11%)
Manning & Napier Advisors, Inc 5,665,135 sh (-16.36%)
Paul Tudor Jones 11,791 sh (-72.45%)
Eaton Vance Worldwide Health Sciences Fund 546,329 sh (-17.92%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:ABT, NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:EW, OTCPK:SNNUF, NAS:ALGN, OTCPK:SONVY, NYSE:TFX, NYSE:VAR, OTCPK:CNVVY, OTCPK:WILLF, OTCPK:CHEOY, NAS:ABMD, NAS:MASI, OTCPK:GGNDF, OTCPK:FSPKF, OTCPK:EKTAY, NAS:NUVA » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDTN.Mexico, MDT.Switzerland, 0QYG.UK,
Headquarter Location:USA
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in four operating segments that manufacture and sell device-based medical therapies.

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, and surgical tools. The company markets its products to health-care institutions and physicians in the United States and overseas. Foreign sales account for about 41% of the company's total sales.

Guru Investment Theses on Medtronic PLC

Jeff Auxier Comments on Medtronic plc - May 09, 2017

Medtronic is a leader in implantable biomedical devices. Back in 2001 the stock traded at 37.5 times earnings and this past quarter traded down to 13 times earnings with a fortress balance sheet and a 7% free cash flow yield. They continue to be a leader in medical technology as their world’s smallest pacemaker, Micra, accelerates US sales driving pacemaker market growth. They generate over $5 billion in free cash flow annually.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Gabelli Funds Comments on Medtronic Plc - Aug 04, 2016

Medtronic plc (NYSE:MDT) (1.7%) (MDT – $75.00 – NYSE) cemented its position as the largest manufacturer of medical devices in the world with last year’s $50 billion acquisition of Covidien. This deal, structured as a tax inversion, should both improve the company’s growth rate and give it better access to its global cash flow. Meanwhile, Medtronic is accelerating its own growth rate through improved management execution and a full pipeline of new heart valves, drug coated balloons, and defibrillators. Medtronic will be the partner of choice for hospitals going forward, and the Covidien deal will allow the company to continue to return at least 50% of its cash flow to shareholders via share buybacks and dividends.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Medtronic PLC

Jeff Auxier Comments on Medtronic plc Guru stock highlight
Medtronic is a leader in implantable biomedical devices. Back in 2001 the stock traded at 37.5 times earnings and this past quarter traded down to 13 times earnings with a fortress balance sheet and a 7% free cash flow yield. They continue to be a leader in medical technology as their world’s smallest pacemaker, Micra, accelerates US sales driving pacemaker market growth. They generate over $5 billion in free cash flow annually. Read more...
52-Week Company Lows Prices tumble for Coca-Cola, Medtronic, Nike, Simon Property, Kimberly-Clark, Estee Lauder
According to GuruFocus’ list, these stocks have reached their 52-week lows. Read more...
Weekly Top Insider Buys Highlights The largest buys were Medtronic, United Technologies, TransDigm Group and Spirit AeroSystems Holdings
The largest insider buys of the week were for Medtronic PLC (NYSE:MDT), United Technologies Corp. (NYSE:UTX), TransDigm Group Inc. (NYSE:TDG) and Spirit AeroSystems Holdings Inc. (NYSE:SPR). Read more...
52-Week Company Lows Coca-Cola, Medtronic, Simon Property Group, Kimberly-Clark, Estee Lauder, Hormel Foods prices fall
According to GuruFocus list of 52-week lows, these stocks have reached their 52-week lows. Read more...
Medtronic Misses 2nd Quarter Revenue Expectations Medical device company releases second-quarter earnings
Medtronic PLC (NYSE:MDT) released the results of the second quarter of 2017 on Nov. 22. The medical technology and services company headquartered in Dublin, Ireland, and traded on the NYSE reported non-GAAP diluted earnings per share of $1.12, beating analysts’ expectations by one cent, generating a surprise of only 0.90%. Read more...
Samuel Isaly Makes 9 New Buys in 3rd Quarter 5 acquisitions have impacts greater than 2% on portfolio
Samuel Isaly (Trades, Portfolio) of Eaton Vance Worldwide Health Sciences Fund acquired nine new holdings in the third quarter ended Aug. 31. Five of the holdings had impacts greater than 2% on the portfolio. Read more...
Barrow, Hanley, Mewhinney & Strauss Reduces Stakes in 2nd Quarter Guru sells shares in Honeywell, Ford, Johnson & Johnson
Barrow, Hanley, Mewhinney & Strauss trimmed existing stakes in six of its top 10 transactions in the second quarter. Read more...
Dividend Aristocrat Correlation Pairs A look at how to pair investment ideas
On June 27, I published an article discussing pairing Dividend Aristocrats based on their correlations. Read more...
Gabelli Funds Comments on Medtronic Plc Guru stock highlight
Medtronic plc (NYSE:MDT) (1.7%) (MDT – $75.00 – NYSE) cemented its position as the largest manufacturer of medical devices in the world with last year’s $50 billion acquisition of Covidien. This deal, structured as a tax inversion, should both improve the company’s growth rate and give it better access to its global cash flow. Meanwhile, Medtronic is accelerating its own growth rate through improved management execution and a full pipeline of new heart valves, drug coated balloons, and defibrillators. Medtronic will be the partner of choice for hospitals going forward, and the Covidien deal will allow the company to continue to return at least 50% of its cash flow to shareholders via share buybacks and dividends. Read more...
T Rowe Price Buys Apple and 2 Other Companies Equity income fund reports its 2nd-quarter portfolio
The “father of growth investing,” Thomas Rowe Price founded the T Rowe Price Equity Income Fund October 1985. While Price prefers a growth-oriented approach to investing, the equity income fund invests in stocks using a “conservative, value-oriented” approach. According to its investment strategy, the fund emphasizes strong dividend payout and undervaluation. With this approach, the mutual fund can reduce its risk more than just investing in growth stocks. Read more...

Ratios

vs
industry
vs
history
PE Ratio 29.93
MDT's PE Ratio is ranked higher than
50% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. MDT: 29.93 )
Ranked among companies with meaningful PE Ratio only.
MDT' s PE Ratio Range Over the Past 10 Years
Min: 10.17  Med: 20.5 Max: 54.09
Current: 29.93
10.17
54.09
Forward PE Ratio 17.24
MDT's Forward PE Ratio is ranked higher than
88% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. MDT: 17.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 29.93
MDT's PE Ratio without NRI is ranked lower than
51% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. MDT: 29.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
MDT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.17  Med: 20.5 Max: 54.09
Current: 29.93
10.17
54.09
Price-to-Owner-Earnings 22.37
MDT's Price-to-Owner-Earnings is ranked higher than
70% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. MDT: 22.37 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MDT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.24  Med: 18.92 Max: 36.13
Current: 22.37
9.24
36.13
PB Ratio 2.35
MDT's PB Ratio is ranked higher than
63% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. MDT: 2.35 )
Ranked among companies with meaningful PB Ratio only.
MDT' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 2.81 Max: 6.08
Current: 2.35
1.78
6.08
PS Ratio 4.04
MDT's PS Ratio is ranked lower than
58% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MDT: 4.04 )
Ranked among companies with meaningful PS Ratio only.
MDT' s PS Ratio Range Over the Past 10 Years
Min: 1.92  Med: 3.53 Max: 5.45
Current: 4.04
1.92
5.45
Price-to-Free-Cash-Flow 22.95
MDT's Price-to-Free-Cash-Flow is ranked higher than
61% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. MDT: 22.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MDT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.18  Med: 14.73 Max: 55.92
Current: 22.95
9.18
55.92
Price-to-Operating-Cash-Flow 18.41
MDT's Price-to-Operating-Cash-Flow is ranked higher than
55% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. MDT: 18.41 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MDT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.13  Med: 12.76 Max: 25.78
Current: 18.41
8.13
25.78
EV-to-EBIT 24.48
MDT's EV-to-EBIT is ranked higher than
97% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. MDT: 24.48 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 15.8 Max: 31.1
Current: 24.48
8.7
31.1
EV-to-EBITDA 16.10
MDT's EV-to-EBITDA is ranked higher than
97% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. MDT: 16.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 13.2 Max: 23.6
Current: 16.1
7.3
23.6
PEG Ratio 7.29
MDT's PEG Ratio is ranked lower than
77% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.52 vs. MDT: 7.29 )
Ranked among companies with meaningful PEG Ratio only.
MDT' s PEG Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.99 Max: 25.64
Current: 7.29
1.1
25.64
Shiller PE Ratio 29.26
MDT's Shiller PE Ratio is ranked higher than
82% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. MDT: 29.26 )
Ranked among companies with meaningful Shiller PE Ratio only.
MDT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.42  Med: 23.12 Max: 43.79
Current: 29.26
14.42
43.79
Current Ratio 1.77
MDT's Current Ratio is ranked lower than
69% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. MDT: 1.77 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.39 Max: 6.8
Current: 1.77
0.88
6.8
Quick Ratio 1.48
MDT's Quick Ratio is ranked lower than
60% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. MDT: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.88 Max: 6.46
Current: 1.48
0.66
6.46
Days Inventory 142.75
MDT's Days Inventory is ranked lower than
56% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. MDT: 142.75 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 132.14  Med: 142.57 Max: 164.01
Current: 142.75
132.14
164.01
Days Sales Outstanding 67.79
MDT's Days Sales Outstanding is ranked higher than
52% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. MDT: 67.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.41  Med: 81.9 Max: 92.09
Current: 67.79
70.41
92.09
Days Payable 61.65
MDT's Days Payable is ranked higher than
52% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. MDT: 61.65 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 32.49  Med: 51.72 Max: 93.14
Current: 61.65
32.49
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.05
MDT's Dividend Yield % is ranked higher than
68% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 1.33 vs. MDT: 2.05 )
Ranked among companies with meaningful Dividend Yield % only.
MDT' s Dividend Yield % Range Over the Past 10 Years
Min: 0.76  Med: 1.92 Max: 2.93
Current: 2.05
0.76
2.93
Dividend Payout Ratio 0.59
MDT's Dividend Payout Ratio is ranked lower than
57% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. MDT: 0.59 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MDT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.18  Med: 0.31 Max: 0.61
Current: 0.59
0.18
0.61
3-Year Dividend Growth Rate 13.50
MDT's 3-Year Dividend Growth Rate is ranked higher than
62% of the 81 Companies
in the Global Medical Devices industry.

( Industry Median: 8.00 vs. MDT: 13.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MDT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 7.6  Med: 16.7 Max: 30.2
Current: 13.5
7.6
30.2
Forward Dividend Yield % 2.03
MDT's Forward Dividend Yield % is ranked higher than
64% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. MDT: 2.03 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.33
MDT's 5-Year Yield-on-Cost % is ranked higher than
76% of the 219 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. MDT: 3.33 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MDT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.24  Med: 3.12 Max: 4.76
Current: 3.33
1.24
4.76
3-Year Average Share Buyback Ratio -11.30
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. MDT: -11.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: 0 Max: 2.5
Current: -11.3
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.35
MDT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. MDT: 1.35 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 2.01 Max: 8.6
Current: 1.35
0.76
8.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.80
MDT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
72% of the 25 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. MDT: 2.80 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.15
MDT's Price-to-Median-PS-Value is ranked lower than
55% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. MDT: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.16 Max: 3.58
Current: 1.15
0.42
3.58
Earnings Yield (Greenblatt) % 4.08
MDT's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. MDT: 4.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 11.5
Current: 4.08
3.2
11.5
Forward Rate of Return (Yacktman) % 7.83
MDT's Forward Rate of Return (Yacktman) % is ranked lower than
52% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. MDT: 7.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 6.6  Med: 13.9 Max: 19.5
Current: 7.83
6.6
19.5

More Statistics

Revenue (TTM) (Mil) $29,361
EPS (TTM) $ 2.83
Beta0.87
Short Percentage of Float0.48%
52-Week Range $69.35 - 89.27
Shares Outstanding (Mil)1,368.88

Analyst Estimate

Apr17 Apr18 Apr19
Revenue (Mil $) 29,675 30,836 32,270
EPS ($) 4.56 4.91 5.35
EPS without NRI ($) 4.56 4.91 5.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.52%
Dividends per Share ($) 1.68 1.92 2.28
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Goldman Sachs Rates Health Care Stocks May 17 2017 
Jeff Auxier Comments on Medtronic plc May 09 2017 
Jeff Auxier's Spring 2017 Market Commentary May 09 2017 
Richard Pzena Invests in 3 Health Care Companies May 09 2017 
T. Rowe Price Keeps Buying Philip Morris, Wells Fargo, Others Apr 24 2017 
Is Cardinal Health a Better Bargain Than Ever? Apr 18 2017 
Just Buy It Mar 27 2017 
Primecap Sells NVIDIA, Microsoft, Union Pacific Mar 23 2017 
Dividend Aristocrats: Medtronic vs. Becton, Dickinson & Company Mar 19 2017 
Top 7 Dividend Health Care Stocks Jan 05 2017 

More From Other Websites
3 Stocks In Or Near Buy Range With Earnings Due: Investing Action Plan May 24 2017
Medtronic Enrolls First Patient in Study of IN.PACT(TM) AV Access Drug-Coated Balloon in Patients... May 24 2017
Medtronic Chairman and CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference May 24 2017
A Look at Medtronic’s Recent Stock Performance May 24 2017
Intuitive Surgical Stock Just Hit an All-Time High: Buy, Sell, or Hold? May 24 2017
Analysts’ Recommendations for MDT ahead of Its Fiscal 4Q17 May 24 2017
3 Large-Cap Stocks for Savvy Investors May 23 2017
Will MDT Hit or Miss Analysts’ Earnings Estimates in Fiscal 4Q17? May 23 2017
Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17 May 23 2017
Medtronic (MDT) Q4 Earnings: Stock Likely to Beat Again? May 23 2017
Medtronic’s Fiscal 4Q17 Results: What Can Investors Expect? May 23 2017
[$$] Companies Are Winning the Battle Over Adjusted Earnings May 22 2017
Cool Ways Wearable Technology Is Improving Healthcare May 21 2017
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint May 19 2017
Medtronic's MyCareLink Data on Older Patients Found Positive May 18 2017
Is Helping Diabetics Fitbit's Next Big Opportunity? May 18 2017
Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at... May 18 2017
Medtronic Study Finds High Use of App-Based Remote Cardiac Monitoring Among Older Patients May 17 2017
Medtronic EVP & President Bryan Hanson to Speak at Jefferies 2017 Global Healthcare Conference May 16 2017
Boston's Heart Valve Wins In Face-Off Trial With Rival Medtronic May 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}